Mary Kay Turner
Mary Kay Turner joined BrainStorm in August of 2017 as Vice President of Patient Advocacy and Government Affairs. Ms. Turner joins BrainStorm from Mitsubishi Tanabe Pharma America, where she led Patient Advocacy and Communications activity to support the commercialization of edaravone for ALS. She is a member of the Board of Directors for the ALS Hope Foundation. Mary Kay’s prior industry experience includes Head of State Government Affairs and Advocacy for Bristol-Myers Squibb. In this role, she led a team of government affairs professionals that focused on significant legislative and regulatory issues that promoted and protected the discovery and development of innovative therapies.
In 2016, Mary Kay was appointed to the Arizona Biomedical Research Commission by Arizona Governor Doug Ducey and served a one-year term. Additionally, she serves on the Board of Advisers for the International Cancer Advocacy Network (ICAN) and served on the Board of Directors for Mental Health America for 3 years.
Mary Kay has a BA in Political Science and History from the University of Oregon.